RET and colorectal carcinoma: Biomarker-driven therapy has been gaining prominence in the treatment paradigm for CRC, with several regulatory-approved drugs such as larotrectinib for NTRK fusions, pembrolizumab and dostarlimab for dMMR/MSI-H, and selpercatinib for RET fusion23.